{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T07:56:43Z","timestamp":1783583803792,"version":"3.55.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,4,19]],"date-time":"2013-04-19T00:00:00Z","timestamp":1366329600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1007\/s10549-013-2528-8","type":"journal-article","created":{"date-parts":[[2013,4,18]],"date-time":"2013-04-18T04:33:58Z","timestamp":1366259638000},"page":"145-153","source":"Crossref","is-referenced-by-count":47,"title":["A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer"],"prefix":"10.1007","volume":"139","author":[{"given":"Cynthia X.","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera J.","family":"Suman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Goetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Haluska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Moynihan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Nanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olufunmilayo","family":"Olopade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Pluard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanfang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen X.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Erlichman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gini F.","family":"Fleming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,4,19]]},"reference":[{"issue":"7","key":"2528_CR1","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1158\/0008-5472-CAN-04-3913","volume":"65","author":"LH Saal","year":"2005","unstructured":"Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X, Yu JS, Malmstrom PO, Mansukhani M, Enoksson J et al (2005) PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 65(7):2554\u20132559","journal-title":"Cancer Res"},{"issue":"5670","key":"2528_CR2","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1126\/science.1096502","volume":"304","author":"Y Samuels","year":"2004","unstructured":"Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ et al (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304(5670):554","journal-title":"Science"},{"issue":"8","key":"2528_CR3","doi-asserted-by":"crossref","first-page":"772","DOI":"10.4161\/cbt.3.8.994","volume":"3","author":"KE Bachman","year":"2004","unstructured":"Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S, Konishi H, Karakas B, Blair BG, Lin C et al (2004) The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 3(8):772\u2013775","journal-title":"Cancer Biol Ther"},{"issue":"21","key":"2528_CR4","doi-asserted-by":"crossref","first-page":"7678","DOI":"10.1158\/0008-5472.CAN-04-2933","volume":"64","author":"IG Campbell","year":"2004","unstructured":"Campbell IG, Russell SE, Choong DY, Montgomery KG, Ciavarella ML, Hooi CS, Cristiano BE, Pearson RB, Phillips WA (2004) Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 64(21):7678\u20137681","journal-title":"Cancer Res"},{"issue":"2","key":"2528_CR5","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/gcc.20062","volume":"41","author":"JM Garcia","year":"2004","unstructured":"Garcia JM, Silva J, Pena C, Garcia V, Rodriguez R, Cruz MA, Cantos B, Provencio M, Espana P, Bonilla F (2004) Promoter methylation of the PTEN gene is a common molecular change in breast cancer. Genes Chromosom Cancer 41(2):117\u2013124","journal-title":"Genes Chromosom Cancer"},{"issue":"7152","key":"2528_CR6","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/nature05933","volume":"448","author":"JD Carpten","year":"2007","unstructured":"Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM, Hostetter G, Boguslawski S, Moses TY, Savage S et al (2007) A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448(7152):439\u2013444","journal-title":"Nature"},{"issue":"15","key":"2528_CR7","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1093\/jnci\/92.15.1252","volume":"92","author":"M Barlund","year":"2000","unstructured":"Barlund M, Forozan F, Kononen J, Bubendorf L, Chen Y, Bittner ML, Torhorst J, Haas P, Bucher C, Sauter G et al (2000) Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis. J Natl Cancer Inst 92(15):1252\u20131259","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"2528_CR8","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0002-9440(10)64158-2","volume":"161","author":"CL Andersen","year":"2002","unstructured":"Andersen CL, Monni O, Wagner U, Kononen J, Barlund M, Bucher C, Haas P, Nocito A, Bissig H, Sauter G et al (2002) High-throughput copy number analysis of 17q23 in 3520 tissue specimens by fluorescence in situ hybridization to tissue microarrays. Am J Pathol 161(1):73\u201379","journal-title":"Am J Pathol"},{"issue":"6","key":"2528_CR9","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J, Campone M, Piccart M, Burris HA III, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F et al (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366(6):520\u2013529","journal-title":"N Engl J Med"},{"issue":"23","key":"2528_CR10","doi-asserted-by":"crossref","first-page":"5314","DOI":"10.1200\/JCO.2005.66.130","volume":"23","author":"S Chan","year":"2005","unstructured":"Chan S, Scheulen ME, Johnston S, Mross K, Cardoso F, Dittrich C, Eiermann W, Hess D, Morant R, Semiglazov V et al (2005) Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 23(23):5314\u20135322","journal-title":"J Clin Oncol"},{"issue":"5","key":"2528_CR11","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S1535-6108(03)00275-7","volume":"4","author":"CL Sawyers","year":"2003","unstructured":"Sawyers CL (2003) Will mTOR inhibitors make it as cancer drugs? Cancer Cell 4(5):343\u2013348","journal-title":"Cancer Cell"},{"issue":"4","key":"2528_CR12","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/nrclinonc.2012.21","volume":"9","author":"R Goncalves","year":"2012","unstructured":"Goncalves R, Ma C, Luo J, Suman V, Ellis MJ (2012) Use of neoadjuvant data to design adjuvant endocrine therapy trials for breast cancer. Nat Rev Clin Oncol 9(4):223\u2013229","journal-title":"Nat Rev Clin Oncol"},{"issue":"16","key":"2528_CR13","doi-asserted-by":"crossref","first-page":"7052","DOI":"10.1158\/0008-5472.CAN-05-0917","volume":"65","author":"S-Y Sun","year":"2005","unstructured":"Sun S-Y, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H, Khuri FR (2005) Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 65(16):7052\u20137058","journal-title":"Cancer Res"},{"issue":"3","key":"2528_CR14","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","volume":"66","author":"KE O\u2019Reilly","year":"2006","unstructured":"O\u2019Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL et al (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66(3):1500\u20131508","journal-title":"Cancer Res"},{"issue":"13","key":"2528_CR15","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1038\/sj.onc.1209990","volume":"26","author":"X Wan","year":"2007","unstructured":"Wan X, Harkavy B, Shen N, Grohar P, Helman LJ (2007) Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 26(13):1932\u20131940","journal-title":"Oncogene"},{"key":"2528_CR16","doi-asserted-by":"crossref","unstructured":"Tabernero J, Rojo F, Calvo E, Burris H, Judson I, Hazell K, Martinelli E, Ramon y Cajal S, Jones S, Vidal L et al (2008) Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 26(10):1603\u20131610","DOI":"10.1200\/JCO.2007.14.5482"},{"key":"2528_CR17","unstructured":"Cho DC (2005) Low expression of surrogates for mTOR pathway activation predicts resistance to CCI-779 in patients with advanced renal cell carcinoma (RCC). In: Proceedings of 17th Symp Mol Targets Cancer Thera November 2005, Philadelphia, USA, C137"},{"issue":"15","key":"2528_CR18","doi-asserted-by":"crossref","first-page":"13325","DOI":"10.1074\/jbc.M211398200","volume":"278","author":"V Galvan","year":"2003","unstructured":"Galvan V, Logvinova A, Sperandio S, Ichijo H, Bredesen DE (2003) Type 1 insulin-like growth factor receptor (IGF-IR) signaling inhibits apoptosis signal-regulating kinase 1 (ASK1). J Biol Chem 278(15):13325\u201313332","journal-title":"J Biol Chem"},{"issue":"10","key":"2528_CR19","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1158\/1535-7163.MCT-05-0068","volume":"4","author":"Y Shi","year":"2005","unstructured":"Shi Y, Yan H, Frost P, Gera J, Lichtenstein A (2005) Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor\/insulin receptor substrate-1\/phosphatidylinositol 3-kinase cascade. Mol Cancer Ther 4(10):1533\u20131540","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"2528_CR20","first-page":"364","volume":"63","author":"KN Thimmaiah","year":"2003","unstructured":"Thimmaiah KN, Easton J, Huang S, Veverka KA, Germain GS, Harwood FC, Houghton PJ (2003) Insulin-like growth factor I-mediated protection from rapamycin-induced apoptosis is independent of Ras-Erk1-Erk2 and phosphatidylinositol 3\u2032-kinase-Akt signaling pathways. Cancer Res 63(2):364\u2013374","journal-title":"Cancer Res"},{"issue":"17","key":"2528_CR21","first-page":"4013","volume":"56","author":"C D\u2019Ambrosio","year":"1996","unstructured":"D\u2019Ambrosio C, Ferber A, Resnicoff M, Baserga R (1996) A soluble insulin-like growth factor I receptor that induces apoptosis of tumor cells in vivo and inhibits tumorigenesis. Cancer Res 56(17):4013\u20134020","journal-title":"Cancer Res"},{"issue":"6","key":"2528_CR22","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1073\/pnas.91.6.2181","volume":"91","author":"D Prager","year":"1994","unstructured":"Prager D, Li HL, Asa S, Melmed S (1994) Dominant negative inhibition of tumorigenesis in vivo by human insulin-like growth factor I receptor mutant. Proc Natl Acad Sci USA 91(6):2181\u20132185","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"2528_CR23","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nrc1387","volume":"4","author":"MN Pollak","year":"2004","unstructured":"Pollak MN, Schernhammer ES, Hankinson SE (2004) Insulin-like growth factors and neoplasia. Nat Rev Cancer 4(7):505\u2013518","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"2528_CR24","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1038\/sj.bjc.6603354","volume":"95","author":"SA Byron","year":"2006","unstructured":"Byron SA, Horwitz KB, Richer JK, Lange CA, Zhang X, Yee D (2006) Insulin receptor substrates mediate distinct biological responses to insulin-like growth factor receptor activation in breast cancer cells. Br J Cancer 95(9):1220\u20131228","journal-title":"Br J Cancer"},{"issue":"18","key":"2528_CR25","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1093\/jnci\/92.18.1472","volume":"92","author":"H Yu","year":"2000","unstructured":"Yu H, Rohan T (2000) Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 92(18):1472\u20131489","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"2528_CR26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1023\/A:1006208721167","volume":"56","author":"JL Gooch","year":"1999","unstructured":"Gooch JL, Van Den Berg CL, Yee D (1999) Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-induced cell death-proliferative and anti-apoptotic effects. Breast Cancer Res Treat 56(1):1\u201310","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"2528_CR27","first-page":"48","volume":"50","author":"KJ Cullen","year":"1990","unstructured":"Cullen KJ, Yee D, Sly WS, Perdue J, Hampton B, Lippman ME, Rosen N (1990) Insulin-like growth factor receptor expression and function in human breast cancer. Cancer Res 50(1):48\u201353","journal-title":"Cancer Res"},{"issue":"23","key":"2528_CR28","first-page":"6691","volume":"48","author":"D Yee","year":"1988","unstructured":"Yee D, Cullen KJ, Paik S, Perdue JF, Hampton B, Schwartz A, Lippman ME, Rosen N (1988) Insulin-like growth factor II mRNA expression in human breast cancer. Cancer Res 48(23):6691\u20136696","journal-title":"Cancer Res"},{"issue":"9","key":"2528_CR29","first-page":"4613","volume":"46","author":"KK Huff","year":"1986","unstructured":"Huff KK, Kaufman D, Gabbay KH, Spencer EM, Lippman ME, Dickson RB (1986) Secretion of an insulin-like growth factor-I-related protein by human breast cancer cells. Cancer Res 46(9):4613\u20134619","journal-title":"Cancer Res"},{"issue":"9","key":"2528_CR30","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1158\/0008-5472.CAN-04-4602","volume":"65","author":"JM Carboni","year":"2005","unstructured":"Carboni JM, Lee AV, Hadsell DL, Rowley BR, Lee FY, Bol DK, Camuso AE, Gottardis M, Greer AF, Ho CP et al (2005) Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor. Cancer Res 65(9):3781\u20133787","journal-title":"Cancer Res"},{"issue":"30","key":"2528_CR31","doi-asserted-by":"crossref","first-page":"5161","DOI":"10.1038\/sj.onc.1207659","volume":"23","author":"M Salatino","year":"2004","unstructured":"Salatino M, Schillaci R, Proietti CJ, Carnevale R, Frahm I, Molinolo AA, Iribarren A, Charreau EH, Elizalde PV (2004) Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K\/Akt and p42\/p44 MAPK signaling pathways but not modulation of progesterone receptor activity. Oncogene 23(30):5161\u20135174","journal-title":"Oncogene"},{"key":"2528_CR32","doi-asserted-by":"crossref","unstructured":"Arteaga CL, Kitten LJ, Coronado EB, Jacobs S, Kull FC, Jr, Allred DC, Osborne CK (1989) Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest 84(5):1418\u20131423","DOI":"10.1172\/JCI114315"},{"issue":"1","key":"2528_CR33","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s10911-006-9010-8","volume":"11","author":"D Sachdev","year":"2006","unstructured":"Sachdev D, Yee D (2006) Inhibitors of insulin-like growth factor signaling: a therapeutic approach for breast cancer. J Mammary Gland Biol Neoplasia 11(1):27\u201339","journal-title":"J Mammary Gland Biol Neoplasia"},{"issue":"22","key":"2528_CR34","first-page":"6429","volume":"48","author":"JP Peyrat","year":"1988","unstructured":"Peyrat JP, Bonneterre J, Beuscart R, Djiane J, Demaille A (1988) Insulin-like growth Factor 1 receptors in human breast cancer and their relation to estradiol and progesterone receptors. Cancer Res 48(22):6429\u20136433","journal-title":"Cancer Res"},{"issue":"24","key":"2528_CR35","first-page":"8912","volume":"63","author":"D Burtrum","year":"2003","unstructured":"Burtrum D, Zhu Z, Lu D, Anderson DM, Prewett M, Pereira DS, Bassi R, Abdullah R, Hooper AT, Koo H et al (2003) A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res 63(24):8912\u20138921","journal-title":"Cancer Res"},{"issue":"8","key":"2528_CR36","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1158\/1078-0432.CCR-04-1586","volume":"11","author":"JD Wu","year":"2005","unstructured":"Wu JD, Odman A, Higgins LM, Haugk K, Vessella R, Ludwig DL, Plymate SR (2005) In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors. Clin Cancer Res 11(8):3065\u20133074","journal-title":"Clin Cancer Res"},{"issue":"18","key":"2528_CR37","doi-asserted-by":"crossref","first-page":"6052","DOI":"10.1158\/1078-0432.CCR-10-2979","volume":"17","author":"A Naing","year":"2011","unstructured":"Naing A, Kurzrock R, Burger A, Gupta S, Lei X, Busaidy N, Hong D, Chen HX, Doyle LA, Heilbrun LK et al (2011) Phase I trial of Cixutumumab combined with temsirolimus in patients with advanced cancer. Clin Cancer Res 17(18):6052\u20136060","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2528_CR38","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s10549-011-1910-7","volume":"136","author":"G Fleming","year":"2012","unstructured":"Fleming G, Ma C, Huo D, Sattar H, Tretiakova M, Lin L, Hahn O, Olopade FO, Nanda R, Hoffman P et al (2012) Phase II trial of temsirolimus in patients with metastatic breast cancer. Breast Cancer Res Treat 136(2):355\u2013363","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"2528_CR39","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1200\/JCO.2011.37.4355","volume":"30","author":"S Malempati","year":"2012","unstructured":"Malempati S, Weigel B, Ingle AM, Ahern CH, Carroll JM, Roberts CT, Reid JM, Schmechel S, Voss SD, Cho SY et al (2012) Phase I\/II trial and pharmacokinetic study of Cixutumumab in pediatric patients with refractory solid tumors and Ewing Sarcoma: a report from the children\u2019s oncology group. J Clin Oncol 30(3):256\u2013262","journal-title":"J Clin Oncol"},{"issue":"3","key":"2528_CR40","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2217\/fon.12.8","volume":"8","author":"RP Roop","year":"2012","unstructured":"Roop RP, Ma CX (2012) Endocrine resistance in breast cancer: molecular pathways and rational development of targeted therapies. Future Oncol 8(3):273\u2013292","journal-title":"Future Oncol"},{"key":"2528_CR41","first-page":"648965","volume":"2012","author":"R Nahta","year":"2012","unstructured":"Nahta R (2012) Deciphering the role of insulin-like growth factor-I receptor in trastuzumab resistance. Chemother Res Pract 2012:648965","journal-title":"Chemother Res Pract"},{"issue":"21","key":"2528_CR42","doi-asserted-by":"crossref","first-page":"6773","DOI":"10.1158\/0008-5472.CAN-11-1295","volume":"71","author":"EM Fox","year":"2011","unstructured":"Fox EM, Miller TW, Balko JM, Kuba MG, S\u00e1nchez V, Smith RA, Liu S, Gonz\u00e1lez-Angulo AM, Mills GB, Ye F et al (2011) A Kinome-wide screen identifies the insulin\/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer. Cancer Res 71(21):6773\u20136784","journal-title":"Cancer Res"},{"issue":"24","key":"2528_CR43","doi-asserted-by":"crossref","first-page":"7597","DOI":"10.1158\/0008-5472.CAN-11-1080","volume":"71","author":"X Hou","year":"2011","unstructured":"Hou X, Huang F, Macedo LF, Harrington SC, Reeves KA, Greer A, Finckenstein FG, Brodie A, Gottardis MM, Carboni JM et al (2011) Dual IGF-1R\/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer. Cancer Res 71(24):7597\u20137607","journal-title":"Cancer Res"},{"issue":"22","key":"2528_CR44","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1200\/JCO.2011.39.0708","volume":"30","author":"T Bachelot","year":"2012","unstructured":"Bachelot T, Bourgier C, Cropet C, Ray-Coquard I, Ferrero J-M, Freyer G, Abadie-Lacourtoisie S, Eymard J-C, Debled M, Spa\u00ebth D et al (2012) Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol 30(22):2718\u20132724","journal-title":"J Clin Oncol"},{"issue":"16","key":"2528_CR45","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1200\/JCO.2008.18.8391","volume":"27","author":"J Baselga","year":"2009","unstructured":"Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G et al (2009) Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 27(16):2630\u20132637","journal-title":"J Clin Oncol"},{"issue":"29","key":"2528_CR46","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1038\/onc.2008.49","volume":"27","author":"LS Steelman","year":"2008","unstructured":"Steelman LS, Navolanic PM, Sokolosky ML, Taylor JR, Lehmann BD, Chappell WH, Abrams SL, Wong EW, Stadelman KM, Terrian DM et al (2008) Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors. Oncogene 27(29):4086\u20134095","journal-title":"Oncogene"},{"issue":"15","key":"2528_CR47","doi-asserted-by":"crossref","first-page":"6084","DOI":"10.1158\/0008-5472.CAN-07-6854","volume":"68","author":"K Stemke-Hale","year":"2008","unstructured":"Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, Carey M, Hu Z, Guan Y, Sahin A et al (2008) An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 68(15):6084\u20136091","journal-title":"Cancer Res"},{"key":"2528_CR48","doi-asserted-by":"crossref","unstructured":"Di Nicolantonio F, Arena S, Tabernero J, Grosso S, Molinari F, Macarulla T, Russo M, Cancelliere C, Zecchin D, Mazzucchelli L et al (2010) Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest 120(8):2858-2866.","DOI":"10.1172\/JCI37539"},{"issue":"10","key":"2528_CR49","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1093\/annonc\/mdh388","volume":"15","author":"LA DeGraffenried","year":"2004","unstructured":"DeGraffenried LA, Fulcher L, Friedrichs WE, Grunwald V, Ray RB, Hidalgo M (2004) Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase\/Akt pathway. Ann Oncol 15(10):1510\u20131516","journal-title":"Ann Oncol"},{"issue":"6104","key":"2528_CR50","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1126\/science.1226344","volume":"338","author":"G Iyer","year":"2012","unstructured":"Iyer G, Hanrahan AJ, Milowsky MI, Al-Ahmadie H, Scott SN, Janakiraman M, Pirun M, Sander C, Socci ND, Ostrovnaya I et al (2012) Genome sequencing identifies a basis for everolimus sensitivity. Science 338(6104):221","journal-title":"Science"},{"issue":"9","key":"2528_CR51","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.1158\/0008-5472.CAN-08-4450","volume":"69","author":"RJ Crowder","year":"2009","unstructured":"Crowder RJ, Phommaly C, Tao Y, Hoog J, Luo J, Perou CM, Parker JS, Miller MA, Huntsman DG, Lin L et al (2009) PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. Cancer Res 69(9):3955\u20133962","journal-title":"Cancer Res"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-013-2528-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-013-2528-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-013-2528-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T16:47:15Z","timestamp":1559234835000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-013-2528-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,19]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["2528"],"URL":"https:\/\/doi.org\/10.1007\/s10549-013-2528-8","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,19]]}}}